Lynn Seely

Biography
Lynn Seely, M. D., has served as Lyells President and Chief Executive Officer since December 2022 and has been a member of our board of directors since May 2021. Dr. Seely was also previously the lead independent director for Blueprint Medicines Corporation acquired by Sanofi and a director for TORL Bio Therapeutics. Dr. Seely was formerly President and Chief Executive Officer and a member of the board of directors of Myovant Sciences, Inc., a biopharmaceutical company that gained marketing approval and launched ORGOVYX for men with advanced prostate cancer and MYFEMBREE for women with uterine fibroids and endometriosis. Prior to joining Myovant, Dr. Seely served as the Chief Medical Officer of Medivation, Inc. In this role, Dr. Seely oversaw the development and marketing approval of the blockbuster medicine XTANDI for men with castration-resistant prostate cancer and held leadership roles in drug development collaborations with Pfizer Inc. and Astellas Pharma US, Inc. Prior to joining Medivation, Dr. Seely served as Vice President of Clinical Development at Corgentech Inc., at Cytyc Health Corporation, and at Pro Duct Health, Inc., a medical device company acquired by Cytyc Corporation. Dr. Seely began her industry career in clinical development at Chiron Corporation. In addition to serving on the Lyell Board, Dr. Seely serves on the Board of Managers for Life Science Cares Bay Area. Dr. Seely received a B. A. in journalism from the University of Oklahoma and an M. D. from the University of Oklahoma College of Medicine. She completed her residency and served as Chief Resident in internal medicine at Yale New Haven Hospital, and she completed her fellowship in endocrinology and metabolism at the University of California, San Diego, where she was on faculty before joining industry.